DK3131902T3 - Forbindelser som ROR-gamma-modulatorer - Google Patents

Forbindelser som ROR-gamma-modulatorer Download PDF

Info

Publication number
DK3131902T3
DK3131902T3 DK15718330.2T DK15718330T DK3131902T3 DK 3131902 T3 DK3131902 T3 DK 3131902T3 DK 15718330 T DK15718330 T DK 15718330T DK 3131902 T3 DK3131902 T3 DK 3131902T3
Authority
DK
Denmark
Prior art keywords
ror
compounds
gamma modulators
modulators
gamma
Prior art date
Application number
DK15718330.2T
Other languages
English (en)
Inventor
Johanna Bakonyi
Steven Richard Brunette
Delphine Collin
Robert Owen Hughes
Xiang Li
Robert Sibley
Michael Robert Turner
Lifen Wu
Qiang Zhang
Shuang Liang
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of DK3131902T3 publication Critical patent/DK3131902T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/06Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/10Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
DK15718330.2T 2014-04-14 2015-04-10 Forbindelser som ROR-gamma-modulatorer DK3131902T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461979231P 2014-04-14 2014-04-14
PCT/US2015/025328 WO2015160654A1 (en) 2014-04-14 2015-04-10 Compounds as modulators of ror gamma

Publications (1)

Publication Number Publication Date
DK3131902T3 true DK3131902T3 (da) 2019-09-02

Family

ID=52998264

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15718330.2T DK3131902T3 (da) 2014-04-14 2015-04-10 Forbindelser som ROR-gamma-modulatorer

Country Status (36)

Country Link
US (5) US9242989B2 (da)
EP (2) EP3418280B1 (da)
JP (2) JP6282759B2 (da)
KR (2) KR102410069B1 (da)
CN (3) CN107266450B (da)
AP (1) AP2016009403A0 (da)
AR (2) AR100058A1 (da)
AU (2) AU2015247983B2 (da)
BR (2) BR122020020657B1 (da)
CA (1) CA2944787C (da)
CL (1) CL2016002421A1 (da)
CY (1) CY1122012T1 (da)
DK (1) DK3131902T3 (da)
EA (2) EA031351B1 (da)
ES (1) ES2744299T3 (da)
HK (2) HK1244800A1 (da)
HR (1) HRP20191579T1 (da)
HU (1) HUE045847T2 (da)
IL (2) IL247419B (da)
LT (1) LT3131902T (da)
MA (1) MA46373A (da)
ME (1) ME03513B (da)
MX (1) MX370780B (da)
MY (1) MY182834A (da)
NZ (1) NZ723530A (da)
PE (2) PE20161572A1 (da)
PH (2) PH12016502019A1 (da)
PL (1) PL3131902T3 (da)
PT (1) PT3131902T (da)
RS (1) RS59170B1 (da)
SG (1) SG11201608537SA (da)
SI (1) SI3131902T1 (da)
TW (2) TWI655192B (da)
UA (2) UA120094C2 (da)
UY (1) UY36077A (da)
WO (1) WO2015160654A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03513B (me) * 2014-04-14 2020-04-20 Boehringer Ingelheim Int Jedinjenja kao modulatori za ror gama
FR3030518B1 (fr) * 2014-12-19 2018-03-23 Galderma Research & Development Derives sulfonamides en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t)
EP3845526A1 (en) 2015-05-15 2021-07-07 Aurigene Discovery Technologies Limited Method for the preparation of tetrahydroquinolinone compounds having ror-gamma modulating activity
EP3356366B1 (en) * 2015-10-01 2019-08-28 Boehringer Ingelheim International GmbH Pteridine derivatives as modulators of ror gamma
EA034514B1 (ru) 2015-12-15 2020-02-14 Астразенека Аб Изоиндольные соединения
JP6899391B2 (ja) * 2016-01-20 2021-07-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ガンマのモジュレータとしての化合物
TWI705958B (zh) 2016-12-05 2020-10-01 荷蘭商領導醫藥控股責任有限公司 RORγ調節子
US20200031753A1 (en) 2017-04-06 2020-01-30 Boehringer Ingelheim International Gmbh Cyclopropyl alkyl amines and process for their preparation
CN110730780A (zh) 2017-06-14 2020-01-24 阿斯利康(瑞典)有限公司 用作ROR-γ调节剂的2,3-二氢异吲哚-1-甲酰胺
CN109206346A (zh) * 2017-07-01 2019-01-15 复旦大学 叔胺类衍生物或其盐及其制备方法和用途
CN107903263B (zh) * 2017-12-28 2019-11-12 山东铂源药业有限公司 一种帕布昔利布中间体的合成方法
CN112135611B (zh) 2018-05-03 2023-01-31 江苏恒瑞医药股份有限公司 作为维甲酸相关孤儿受体γ(RORγ)的调节剂的苯并咪唑衍生物及其药物用途
CN112930336A (zh) 2018-10-18 2021-06-08 勃林格殷格翰国际有限公司 光学活性的1-环丙基烷基-1-胺的可放大合成
US20230014730A1 (en) 2019-09-23 2023-01-19 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
CN114502535B (zh) 2019-10-31 2024-04-12 江苏恒瑞医药股份有限公司 一种RORγ调节剂的酸加成盐
WO2022106549A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Crystalline salts of a ror gamma inhibitor
WO2022106551A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Co-crystals of a ror gamma inhibitor
WO2022106548A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Solid forms of a ror gamma inhibitor
WO2022106547A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Process for synthesising a ror gamma inhibitor
WO2022106550A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Crystalline polymorphic form of a ror gamma inhibitor
CN117003757A (zh) * 2022-05-07 2023-11-07 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为usp1抑制剂
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
WO2009022185A2 (en) * 2007-08-16 2009-02-19 Astrazeneca Ab 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use
JP5507567B2 (ja) 2008-09-26 2014-05-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ccr1受容体拮抗薬としてのアザインダゾール化合物
KR20120087923A (ko) 2009-10-21 2012-08-07 베링거 인겔하임 인터내셔날 게엠베하 Ccr1 수용체 길항제로서의 인다졸 및 피라졸로피리딘 화합물
WO2012167046A1 (en) * 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
CN103930425B (zh) * 2012-05-14 2016-04-27 华东理工大学 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用
ME03513B (me) * 2014-04-14 2020-04-20 Boehringer Ingelheim Int Jedinjenja kao modulatori za ror gama
EP3356366B1 (en) * 2015-10-01 2019-08-28 Boehringer Ingelheim International GmbH Pteridine derivatives as modulators of ror gamma
JP6899391B2 (ja) * 2016-01-20 2021-07-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ガンマのモジュレータとしての化合物

Also Published As

Publication number Publication date
PE20161572A1 (es) 2017-02-01
EA031351B1 (ru) 2018-12-28
AR100058A1 (es) 2016-09-07
CN106132965B (zh) 2020-02-07
EP3418280B1 (en) 2023-07-12
JP6463855B2 (ja) 2019-02-06
AU2015247983B2 (en) 2019-05-16
JP2017511357A (ja) 2017-04-20
TW201625622A (zh) 2016-07-16
AP2016009403A0 (en) 2016-08-31
PE20211002A1 (es) 2021-06-01
US20170008894A1 (en) 2017-01-12
JP2018065874A (ja) 2018-04-26
CA2944787A1 (en) 2015-10-22
BR112016021962B1 (pt) 2022-12-13
MX2016013342A (es) 2017-01-26
AU2019203027A1 (en) 2019-05-23
EP3418280A1 (en) 2018-12-26
ES2744299T3 (es) 2020-02-24
EP3131902A1 (en) 2017-02-22
WO2015160654A1 (en) 2015-10-22
PL3131902T3 (pl) 2019-11-29
KR20200040917A (ko) 2020-04-20
PT3131902T (pt) 2019-09-17
CN107266454A (zh) 2017-10-20
PH12020500252A1 (en) 2021-07-26
AU2015247983A1 (en) 2016-09-08
UA121255C2 (uk) 2020-04-27
SG11201608537SA (en) 2016-11-29
US9598415B2 (en) 2017-03-21
SI3131902T1 (sl) 2019-10-30
MX370780B (es) 2020-01-03
ME03513B (me) 2020-04-20
EA201890329A1 (ru) 2018-07-31
CN106132965A (zh) 2016-11-16
TWI655192B (zh) 2019-04-01
PH12016502019B1 (en) 2017-01-09
KR102410069B1 (ko) 2022-06-20
CA2944787C (en) 2023-03-14
LT3131902T (lt) 2019-09-25
JP6282759B2 (ja) 2018-02-21
UY36077A (es) 2015-10-30
KR102410076B1 (ko) 2022-06-22
US20190002465A1 (en) 2019-01-03
BR112016021962A2 (pt) 2023-01-20
US20160075706A1 (en) 2016-03-17
BR122020020657B1 (pt) 2022-12-20
AR119454A2 (es) 2021-12-22
RS59170B1 (sr) 2019-10-31
MY182834A (en) 2021-02-05
MA46373A (fr) 2019-08-07
CN107266450B (zh) 2020-07-24
EP3131902B1 (en) 2019-06-12
IL247419B (en) 2019-03-31
IL263878A (en) 2019-01-31
CY1122012T1 (el) 2020-10-14
KR20160142396A (ko) 2016-12-12
US20150291607A1 (en) 2015-10-15
HK1244801A1 (zh) 2018-08-17
US20180022749A1 (en) 2018-01-25
NZ723530A (en) 2023-05-26
TW201841915A (zh) 2018-12-01
CL2016002421A1 (es) 2017-03-24
HUE045847T2 (hu) 2020-01-28
TWI652268B (zh) 2019-03-01
AU2019203027B2 (en) 2020-07-09
HK1244800A1 (zh) 2018-08-17
HRP20191579T1 (hr) 2019-11-29
PH12016502019A1 (en) 2017-01-09
CN107266454B (zh) 2019-08-09
US9242989B2 (en) 2016-01-26
EA201691978A1 (ru) 2017-02-28
CN107266450A (zh) 2017-10-20
EA035063B1 (ru) 2020-04-23
IL263878B (en) 2019-11-28
UA120094C2 (uk) 2019-10-10

Similar Documents

Publication Publication Date Title
DK3394033T3 (da) Heterocykliske forbindelser som immunmodulatorer
DK3131902T3 (da) Forbindelser som ROR-gamma-modulatorer
MA53943A (fr) Modulateurs de ror-gamma
DK3294713T5 (da) Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer
DK3209778T3 (da) Kombination
DK3097107T3 (da) Diaryl-makrocykler som modulatorer for proteinkinaser
DK3134402T3 (da) 4-amino-imidazoquinolinforbindelser
DK3183051T3 (da) Væske-til-luftmembranenergivekslere
DK3094631T3 (da) Pyrimidinyloxybenzenderivater som herbicider
DK3211743T3 (da) Ø-til-netværk-omskiftningsfremgangsmåde
DK3229810T3 (da) Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
DK3222714T3 (da) Phytasemutanter
DK3119396T3 (da) Muscarinreceptoragonister
DK3006072T3 (da) Karadgang
DK3125898T3 (da) Farmakofor til trail-induktion
CL2016002165A1 (es) Compuestos de aminocarbonilcarbamato
DE112015001664A5 (de) Betätigungsaktuator
BR112016030730A2 (pt) Composto
DK3191466T3 (da) Azetidinyloxyphenylpyrrolidinforbindelser
DK3183340T3 (da) Termolabile exonukleaser
DK3154703T3 (da) Fuldkappe-snekkecentrifuge
DK3110439T3 (da) Pcsk9-vacciner
DK3230929T3 (da) Forbedringer til tælleranordninger
DK3145916T3 (da) Imidazolderivater som formylpeptidreceptormodulatorer
DE112015005041A5 (de) Gargerätevorrichtung